Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

This article was originally published on Nasdaq

Editas Medicine (EDIT) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.